AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1103576
Drug: Clonidine (rapidly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (rapidly falling dosage)
Trial: 31270800
Drug: Inhaled aerosolised
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aerosolised prostacyclin (20 ng/kg/min)
Trial: 31270800
Drug: Inhaled saline
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled saline (NaCl, 9 mg/mL)
Trial: 28911799
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol proprionate (CP)
Trial: 28911799
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone diproprionate (BDP)
Trial: 23955418
Drug: Venlafaxine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (150 mg/day)
Trial: 23955418
Drug: Pregabalin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (200 mg/day)
Trial: 17131249
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% eye drops twice daily
Trial: 17131249
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate eye drops twice daily
Trial: 15590250
Drug: Epidural neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural neostigmine (0.05 mg) with mepivacaine (100 mg)
Trial: 15590250
Drug: Epidural neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural neostigmine (0.1 mg) with mepivacaine (100 mg)
Trial: 15590250
Drug: Epidural neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural neostigmine (0.15 mg) with mepivacaine (100 mg)
Trial: 15590250
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 mg neostigmine) with mepivacaine (100 mg)
Trial: 9463302
Drug: Pectin/chamomile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin/chamomile extract preparation (Diarrhoesan)
Trial: 3525428
Drug: Gabapentin 200-400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 200-400 mg
Trial: 3525428
Drug: Gabapentin 100
RxNorm normalized name: gabapentin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 100 mg
Trial: 3525428
Drug: Gabapentin 50-200
RxNorm normalized name: gabapentin 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 50-200 mg
Trial: 16781073
Drug: Gabapentin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (various doses)
Trial: 28636433
Drug: AGS‐004 dendritic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS‐004 dendritic cell therapy administered monthly after ART initiation during acute HIV infection
Trial: 28636433
Drug: AGS‐004 dendritic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS‐004 dendritic cell therapy
Trial: 25185281
Drug: SIT (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT (standardized allergen vaccine) for 3 years
Trial: 25185281
Drug: ST (symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST (symptomatic therapy)
Trial: 20728275
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of naloxone (0.02 mg/kg)
Trial: 20728275
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of naloxone (0.14 mg/kg)
Trial: 24447629
Drug: Ezetimibe/Simvastatin 10/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin 10/40 mg
Trial: 18266852
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the statin dose
Trial: 16009156
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of levonorgestrel (1.5 mg)
Trial: 16009156
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of levonorgestrel (1.5 mg)
Trial: 10638905
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIVA) with nicomorphine
Trial: 9580247
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (RI)
Trial: 12650950
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg b.i.d.
Trial: 6366809
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg naproxen daily for 7 days
Trial: 6366809
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g acetylsalicylic acid daily for 7 days
Trial: 28840431
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no photobiomodulation therapy)
Trial: 17503668
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (cART) with zidovudine/lamivudine
Trial: 8814744
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir 3% ointment
Trial: 1711089
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (radiation and hyperthermia with bleomycin)
Trial: 6601941
Drug: Propranolol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol therapy continued intraoperatively and postoperatively
Trial: 6601941
Drug: Propranolol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol therapy discontinued
Trial: 31583748
Drug: Cognitively-Based Compassion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitively-Based Compassion Training (CBCT) administered for 20 hours across 8 to 10 weeks to parents (n = 25)
Trial: 26135275
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support intervention; details on dosage and duration not available.
Trial: 23638803
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant (Ozurdex)
Trial: 21185347
Drug: OROS®-methylphenidate hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS®-methylphenidate hydrochloride (MPH) 18, 36 or 72 mg
Trial: 19723572
Drug: Fraxinus excelsior
RxNorm normalized name: FRAXINUS EXCELSIOR LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraxinus excelsior L. seed extract (1.0 g)
Trial: 3544892
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg orally over three days)
Trial: 3544892
Drug: Amodiaquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (25 mg/kg orally over three days)
Trial: 20800193
Drug: Defocused extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Defocused extracorporeal shock wave therapy (ESWT, 100 impulses/cm(2) at 0.1 mJ/mm(2)) applied once to the donor site, immediately after skin harvest
Trial: 20800193
Drug: Standard topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard topical therapy (nonadherent silicone mesh and antiseptic gel) without ESWT
Trial: 10736124
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) administered for 100 minutes (150 mg/kg over 1 hour followed by 14 mg/kg per hour for 40 minutes)
Trial: 9369111
Drug: 2 liters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 liters of polyethylene glycol solution combined with a laxative (Group A)
Trial: 9369111
Drug: 4 liters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 liters of polyethylene glycol solution (Group B)
Trial: 9952267
Drug: Phenytoin (PHT)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT) monotherapy
Trial: 3994616
Drug: dimenhydrinate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dimenhydrinate (50 mg)
Trial: 3994616
Drug: promethazine hydrochloride
RxNorm normalized name: Promethazine Hydrochloride
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: promethazine hydrochloride (25 mg)
Trial: 3994616
Drug: mixture (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixture (25 mg promethazine plus 10 mg d-amphetamine)
Trial: 3994616
Drug: promethazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine (50 mg)
Trial: 30023451
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing and Cognitive Behavioural Therapy (MI-CBT) in addition to Treatment as Usual (TAU)
Trial: 28701387
Drug: Moderate iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate iron status (serum ferritin 12-75 μg/L)
Trial: 28701387
Drug: High iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High iron status (serum ferritin ≥75 μg/L)
Trial: 28701387
Drug: High iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High iron status with normal serum soluble transferrin receptor concentration (<8.3 mg/L)
Trial: 28701387
Drug: Deficient iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deficient iron status (serum ferritin <12 or <15 μg/L)
Trial: 24093978
Drug: Ormeloxifene 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ormeloxifene 30 mg, twice a week for 3 months
Trial: 21962052
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L O2 · min(‐1)
Trial: 21962052
Drug: 3 L
RxNorm normalized name: D3 Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 L O2 · min(‐1)
Trial: 18267048
Drug: Chlorhexidine-neomycin cream
RxNorm normalized name: chlorhexidine / neomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-neomycin cream and nasal cautery
Trial: 18267048
Drug: Chlorhexidine-neomycin cream
RxNorm normalized name: chlorhexidine / neomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-neomycin cream alone
Trial: 16894588
Drug: Treatment-resistant late-onset
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-resistant late-onset depressive disorder
Trial: 16894588
Drug: Treatment-responsive late-onset
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-responsive late-onset depressive disorder
Trial: 9046503
Drug: External cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External cooling system with bupivacaine/morphine
Trial: 21123342
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention (systematic health education, intensive and individualised intervention, treatment, and rehabilitation)
Trial: 15669709
Drug: One-stage procedure
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage procedure with a two-piece implant and a 3-month healing period (Group A)
Trial: 15669709
Drug: Two-stage procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage procedure with a two-piece implant and a 3-month healing period (Group B - Control Group)
Trial: 15669709
Drug: One-stage procedure
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage procedure with a one-piece implant and a 3-month healing period (Group C)
Trial: 15669709
Drug: One-stage surgical
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage surgical procedure with a two-piece implant and early loading (within 3 weeks) (Group D)
Trial: 11352436
Drug: Moxifloxacin 100mg
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 100mg twice daily
Trial: 11352436
Drug: Moxifloxacin 200mg
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 200mg twice daily
Trial: 23993130
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400mg once daily
Trial: 11352436
Drug: Moxifloxacin 600mg
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 600mg once daily
Trial: 9229034
Drug: Antimanic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimanic treatment (specifics not provided)
Trial: 8105716
Drug: 0.105 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.105 mg/kg MIV (1.5 x ED95) and H1/H2 antagonist
Trial: 8105716
Drug: 0.105 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.105 mg/kg MIV and placebo
Trial: 8105716
Drug: 0.21 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.21 mg/kg MIV (3 x ED95) and H1/H2 antagonist
Trial: 8105716
Drug: 0.21 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.21 mg/kg MIV and placebo
Trial: 3145665
Drug: Cimetidine 1200
RxNorm normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1200 mg, q.i.d. for 4 weeks
Trial: 27793166
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2b therapy at 1.5 mcg/kg for 48 weeks
Trial: 27793166
Drug: HBsAg <1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg <1500 IU/mL at week 12
Trial: 27793166
Drug: HBsAg decrease
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg decrease >1.5 logIU/mL at week 12
Trial: 27793166
Drug: HBsAg >20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg >20,000 IU/mL at week 12
Trial: 27793166
Drug: HBsAg >20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg >20,000 IU/mL at week 24
Trial: 24346752
Drug: Haloperidol 15
RxNorm normalized name: haloperidol 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 15 mg
Trial: 24346752
Drug: Olanzapine 20
RxNorm normalized name: olanzapine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 20 mg
Trial: 24346752
Drug: Risperidone 2
RxNorm normalized name: risperidone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 2 to 6 mg
Trial: 24188719
Drug: LINDA intervention
RxNorm normalized name: Lindane
DrugBank: Lindane (DB00431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LINDA intervention (n = 1,537) received a 20‐minute individualized lifestyle counseling session followed by further support at six‐monthly follow-ups for 1.5‐2.5 years.
Trial: 18423009
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 10 mg administered at 9 p.m. for four nights
Trial: 18423009
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 9 p.m. for four nights
Trial: 8916314
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDA) 12 mg/m2/d for 3 days and cytosine arabinoside (Ara‐C) 100 mg/m2/d for 7 days
Trial: 1858985
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg IV) pretreatment before tracheal extubation
Trial: 26905266
Drug: Mesalazine modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine modified-release tablets (MR group, n = 126)
Trial: 26905266
Drug: Other enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other enteric-coated tablets (EC group, n = 125)
Trial: 21512102
Drug: Intensive reading
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive reading intervention (50-minute daily sessions in groups of 2-4 students)
Trial: 19175878
Drug: lamivudine +
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine + vaccine + HBIg
Trial: 19175878
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + vaccine + HBIg
Trial: 15889321
Drug: Postprandial aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial aspart insulin
Trial: 15889321
Drug: Preprandial aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial aspart insulin
Trial: 15889321
Drug: Both preprandial
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preprandial and postprandial aspart insulin
Trial: 2666559
Drug: Non-pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological therapy (started after 1 year for G1)
Trial: 2666559
Drug: Non-pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological therapy (used from the beginning for G2)
Trial: 2666559
Drug: Non-pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological therapy (for both groups)
Trial: 24142473
Drug: Besifloxacin ophthalmic
RxNorm normalized name: besifloxacin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifloxacin ophthalmic suspension 0.6 %
Trial: 17685683
Drug: Contrast Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast Water Therapy (CWT)
Trial: 16237983
Drug: Intravascular irradiation
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular irradiation therapy
Trial: 9428121
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams a day of oral acyclovir for 16 weeks after transplantation
Trial: 8515787
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of vesnarinone per day
Trial: 8515787
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of vesnarinone per day
Trial: 31662037
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intra-arterial therapies
Trial: 26079223
Drug: 1.2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/d GAA
Trial: 26079223
Drug: 2.4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/d GAA
Trial: 26079223
Drug: 4.8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 g/d GAA
Trial: 21650082
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of perindopril erbumine 4 mg
Trial: 21650082
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of perindopril erbumine 4 mg
Trial: 19167636
Drug: Cibenzoline (Cib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (Cib, 70 mg)
Trial: 19167636
Drug: Pilsicainide (Pil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide (Pil, 50 mg)
Trial: 25317365
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg twice daily
Trial: 16750796
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (including gabapentin, venlafaxine, amitriptyline)
Trial: 7509573
Drug: Child-centered therapy
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-centered therapy
Trial: 10806698
Drug: Oxytocin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (20 IU injected into uterine muscle and 20 IU intravenous injection immediately after delivery)
Trial: 29528117
Drug: Dopamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (2 μg kg-1 min-1)
Trial: 26951940
Drug: Doxycycline 40‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 40‐mg modified‐release capsules
Trial: 24721108
Drug: Internet-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based guided self-help intervention based on problem-solving therapy for glioma patients with depressive symptoms.
Trial: 23570677
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (8 g magnesium sulphate heptahydrate in 50 ml infusion over 30 minutes)
Trial: 23570677
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic sodium chloride solution 0.9% in 50 ml infusion over 30 minutes)
Trial: 19308807
Drug: Continued medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medical therapy (control group)
Trial: 8024262
Drug: Scopolamine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (low and medium doses)
Trial: 28096208
Drug: Alteplase administered
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase administered at the CT scanner